Intellia Therapeutics (NTLA) Other Non Operating Income (2021 - 2026)

Intellia Therapeutics (NTLA) has 6 years of Other Non Operating Income data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 33.61% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $26.1 million, a 72.37% increase from a year earlier, with the FY2025 full-year figure at $28.3 million, up 85.64% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $4.3 million, up from $2.9 million in the prior quarter.
• Over the last five years, Other Non Operating Income for NTLA reached as high as $10.2 million in Q3 2025 and fell as low as -$7.9 million in Q2 2024.
• Historically, Other Non Operating Income has averaged $3.9 million across 5 years, with a median of $6.6 million in 2024.
• Across the five-year window, Other Non Operating Income sank 2306.02% in 2022 and jumped 464.03% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at -$3.3 million in 2022, then surged by 332.86% to $7.7 million in 2023, then retreated by 2.35% to $7.5 million in 2024, then sank by 61.27% to $2.9 million in 2025, then surged by 47.09% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $4.3 million in Q1 2026, $2.9 million in Q4 2025, and $10.2 million in Q3 2025.